Atonomics and Beckman Coulter Enter Agreement for Equity Investment

Investment will Aid Atonomics in Development of Near Patient Tests on New Atolyzer® Platform.

Atonomics A/S announced today that it has entered into an agreement with Beckman Coulter, Inc. (NYSE: BEC) which will enable Atonomics to advance its development of diagnostic tests on its Atolyzer® system to address several important clinical markets including cardiology, maternal health and prostate cancer. As part of the transaction, Beckman Coulter is taking a minority equity stake in Atonomics. The Atolyzer platform, which is currently under development, will be a fully integrated immuno‐diagnostic system designed to deliver central laboratory performance in a near‐patient setting.

“The Atolyzer device combines small size and portability in a system that is based on well‐ established chemistries, reagents, and technologies. We look forward to assisting Atonomics in moving this technology toward commercialization,” said Richard Creager, group vice president of Immunoassay and Molecular Diagnostics at Beckman Coulter.

“We are extremely pleased to enter into this agreement with Beckman Coulter, a company dedicated to high quality central laboratory testing with a global leadership position in immunoassays,” said Thomas Warthoe, Atonomics’ CEO. “Its investment recognizes the unique benefits and broad applicability that the Atolyzer platform will bring to the diagnostics industry. We believe the Atolyzer system will be an ideal near‐patient partner to Beckman Coulter’s fully automated Access® and UniCel Dxl® platforms. Industry collaborations like this one are an important part of Atonomics’ business strategy.”

Atonomics believes the Atolyzer technology will bridge the performance gap between central laboratory and point‐of‐care analyzers that can be operated in critical care settings such as emergency departments.

Atonomics is today owned by majority shareholders Inventages Venture Capital, Sunstone Capital and NeuroSearch, who continue to support and believe in the company’s strategy and welcome Beckman Coulter as a new strategic investor in the company.

FOR IMMEDIATE RELEASE

About Atonomics Atonomics is an emerging technology company based in Copenhagen, Denmark, that designs and manufactures the innovative Atolyzer® Platform for near‐patient testing in hospitals, clinics, physician offices and patient monitoring. Atonomics is pursuing a strategy to partner with leading players in the industry to bring a new dimension of quality to the POCT market. The Atolyzer® platform is a platform for immuno‐diagnostic and molecular diagnostic testing. The Atolyzer® is designed for simplicity and ease of use while preserving performance and safety. The stand‐alone device is operated with a single touch by any health worker and can be positioned in any location throughout the hospital, clinic or office where large systems cannot operate, representing true near‐patient testing. For more information, visit www.atonomics.com.

About Beckman Coulter Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 275,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating‐type lease payments, represent about 80% of the company’s 2010 revenue of $3.7 billion. For more information, visit www.beckmancoulter.com.

Note on Forward‐Looking Statements This press release contains ”forward‐looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including the statement by Richard Creager regarding the development and potential commercialization of the Atolyzer device. These statements are based on current expectations and assumptions. Actual results could differ materially from those anticipated by these forward‐looking statements as a result of a number of risks and uncertainties, some of which may be beyond the control of Atonomics and/or Beckman Coulter. Factors that might cause such a difference include, but are not limited to, the risks and uncertainties involved in the development and integration of new technologies, and should be considered along with and in conjunction to all other risks detailed in Beckman Coulter’s public filings with the SEC from time to time, including Beckman Coulter’s most recently filed Annual Report on Form 10‐K for the year ended December 31, 2010 and its subsequently‐filed SEC reports. The reader is cautioned not to unduly rely on these forward‐looking statements. Each of Atonomics and Beckman Coulter expressly disclaims any intent or obligation to update or revise publicly these forward‐looking statements except as required by law.

Trace® is now ready for ordering

€ 2495 Trace® device                
€ 15 each Lipids capsule  
€ 120 for 10 Lipids capsules

We will on a continuous basis release more and more important biomarker capsules.

Trace is available now for you that wishes to get started with this important biomarker monitoring device.


From 2018 we will have semi-automated important production procedures and thus can sell at a lower price. 

We allow you to pre-order now for below pricing with delivery time before end of April 2018.

€ 695 Trace® device
€ 15 each Lipids capsule or
€ 120 for 10 Lipids capsules

Orders will be shipped on a first incoming order basis.

Continue ordering